Last reviewed · How we verify
RBN-2397
At a glance
| Generic name | RBN-2397 |
|---|---|
| Also known as | Pembrolizumab, Keytruda |
| Sponsor | Ribon Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- RBN-2397 in Combination With Pembrolizumab in Patients With SCCL (PHASE1, PHASE2)
- Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RBN-2397 CI brief — competitive landscape report
- RBN-2397 updates RSS · CI watch RSS
- Ribon Therapeutics, Inc. portfolio CI